These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 10495037

  • 1. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.
    Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B, Calderaro C, Felici L, Stocchi F, Meco G, Amenta F, Lenzi GL.
    Mov Disord; 1999 Sep; 14(5):764-71. PubMed ID: 10495037
    [Abstract] [Full Text] [Related]

  • 2. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease.
    Barbanti P, Fabbrini G, Ricci A, Bruno G, Cerbo R, Bronzetti E, Amenta F, Luigi Lenzi G.
    Mech Ageing Dev; 2000 Dec 01; 120(1-3):65-75. PubMed ID: 11087905
    [Abstract] [Full Text] [Related]

  • 3. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study.
    Amenta F, Bronzetti E, Felici L, Ricci A, Tayebati SK.
    J Auton Pharmacol; 1999 Jun 01; 19(3):151-9. PubMed ID: 10511471
    [Abstract] [Full Text] [Related]

  • 4. Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study.
    Ricci A, Bronzetti E, Felici L, Greco S, Amenta F.
    J Neuroimmunol; 1998 Dec 01; 92(1-2):191-5. PubMed ID: 9916894
    [Abstract] [Full Text] [Related]

  • 5. Age-dependent changes in the expression of dopamine receptor subtypes in human peripheral blood lymphocytes.
    Barili P, Bronzetti E, Felici L, Ferrante F, Ricci A, Zaccheo D, Amenta F.
    J Neuroimmunol; 1996 Dec 01; 71(1-2):45-50. PubMed ID: 8982102
    [Abstract] [Full Text] [Related]

  • 6. Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives.
    Ricci A, Bronzetti E, Mulatero P, Schena M, Veglio F, Amenta F.
    Hypertension; 1997 Dec 01; 30(6):1566-71. PubMed ID: 9403584
    [Abstract] [Full Text] [Related]

  • 7. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine?
    Barbanti P, Bronzetti E, Ricci A, Cerbo R, Fabbrini G, Buzzi MG, Amenta F, Lenzi GL.
    Neurosci Lett; 1996 Mar 29; 207(2):73-6. PubMed ID: 8731424
    [Abstract] [Full Text] [Related]

  • 8. Postnatal development of dopamine receptor expression in rat peripheral blood lymphocytes.
    Tomassoni D, Bronzetti E, Cantalamessa F, Mignini F, Ricci A, Sabbatini M, Tayebati SK, Zaccheo D.
    Mech Ageing Dev; 2002 Mar 15; 123(5):491-8. PubMed ID: 11796134
    [Abstract] [Full Text] [Related]

  • 9. [3H]spiperone binding to lymphocyte in extrapyramidal disease and in aging.
    Członkowska A, Jachowicz-Jeszka J, Członkowski A.
    Brain Behav Immun; 1987 Sep 15; 1(3):197-203. PubMed ID: 2975511
    [Abstract] [Full Text] [Related]

  • 10. Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT.
    Ricci A, Veglio F, Amenta F.
    J Neuroimmunol; 1995 May 15; 58(2):139-44. PubMed ID: 7759603
    [Abstract] [Full Text] [Related]

  • 11. Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease.
    Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.
    CNS Neurol Disord Drug Targets; 2024 May 15; 23(4):476-487. PubMed ID: 36999711
    [Abstract] [Full Text] [Related]

  • 12. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
    Hurley MJ, Mash DC, Jenner P.
    Eur J Neurosci; 2003 Nov 15; 18(9):2668-72. PubMed ID: 14622169
    [Abstract] [Full Text] [Related]

  • 13. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.
    Wood M, Dubois V, Scheller D, Gillard M.
    Br J Pharmacol; 2015 Feb 15; 172(4):1124-35. PubMed ID: 25339241
    [Abstract] [Full Text] [Related]

  • 14. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study.
    Ricci A, Amenta F.
    J Neuroimmunol; 1994 Aug 15; 53(1):1-7. PubMed ID: 8051291
    [Abstract] [Full Text] [Related]

  • 15. A post-mortem study on striatal dopamine receptors in Parkinson's disease.
    Rinne JO, Laihinen A, Lönnberg P, Marjamäki P, Rinne UK.
    Brain Res; 1991 Aug 09; 556(1):117-22. PubMed ID: 1834312
    [Abstract] [Full Text] [Related]

  • 16. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
    Tice MA, Hashemi T, Taylor LA, Duffy RA, McQuade RD.
    Pharmacol Biochem Behav; 1994 Nov 09; 49(3):567-71. PubMed ID: 7862709
    [Abstract] [Full Text] [Related]

  • 17. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ.
    Parkinsonism Relat Disord; 2009 Dec 09; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [Abstract] [Full Text] [Related]

  • 18. [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].
    Tadori Y, Kobayashi H.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Nov 09; 34(5-6):127-32. PubMed ID: 25536763
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG.
    Drugs; 1998 Nov 09; 55 Suppl 1():10-6. PubMed ID: 9483165
    [Abstract] [Full Text] [Related]

  • 20. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes.
    Barbanti P, Fabbrini G, Ricci A, Pascali MP, Bronzetti E, Amenta F, Lenzi GL, Cerbo R.
    Cephalalgia; 2000 Feb 09; 20(1):15-9. PubMed ID: 10817442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.